Press Releases Race Oncology Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:10:13 2024-06-06 am EDT			5-day change	1st Jan Change
1.75 ^AUD	+11.46%		+21.95%	+108.33%

Mar. 26	Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	MT
Mar. 18	Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	CI

Race Oncology's breakthrough in cancer cell treatment	May. 15	AQ
Race Oncology looks to accelerate clinical development of bisantrene	Feb. 28	AQ
Race Oncology appoints Dr Daniel Tillett as CEO	Nov. 23	AQ
Race Oncology highlights impressive bisantrene clinical data	Nov. 07	AQ
Race Oncology kicks off safety studies for RC220	23-10-09	AQ
Race Oncology at the heart of cancer care	23-08-09	AQ
Race Oncology announces deal with manufacturer Ardena to develop companyÃ¢€™s new IV formulation RC220	23-07-19	AQ
Race Oncology poised for observational heart protection breast cancer trial	23-03-14	AQ
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as companyÃ¢€™s new Managing Director/CEO	22-12-15	AQ
Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO	22-12-15	EQ
Race Oncology welcomes positive pre-IND meeting for Zantrene	22-11-24	AQ
Race Oncology welcomes positive pre-IND meeting for Zantrene	22-11-24	EQ
Race Oncology : Update - Notification of buy-back - RAC	22-07-27	PU
Race Oncology : RAC Quarterly Investor Presentation	22-07-27	PU
Race Oncology : Update - Notification of buy-back - RAC	22-07-25	PU
Race Oncology : Quarterly Activity Report & Appendix 4C	22-07-21	PU
Race Oncology : EMD AML MDS Trial Expands to Europe	22-06-07	PU
Race Oncology : Quarterly Activity Report & Appendix 4C	22-04-20	PU
Race Oncology : Zantrene highly effective in EMD AML Mouse Model	22-03-16	PU
Race Oncology : ASX Small and Mid-Cap Conference Presentation	22-03-14	PU

No results for this search